- All Courts
- Federal Courts
- Bankruptcies
- PTAB
- ITC
Azurity Pharmaceuticals, Inc. v. Alkem Laboratories Ltd.
Case Type | 835 Patent - Abbreviated New Drug Application (ANDA) |
Tags | 835 Patent, Abbreviated New Drug Application, Anda, 835 Patent, Abbreviated New Drug Application, Anda |
Plaintiff - Appellant | AZURITY PHARMACEUTICALS, INC. |
Defendant - Appellee | ALKEM LABORATORIES LTD. |

- Search within this case
Analyze Party
Analyze Firm
Celgene Corporation v. Hetero Labs Limited
Case Type | 830 Patent |
Tags | 830 Patent, 830 Patent |
Plaintiff - Appellant | CELGENE CORPORATION |
Defendant | HETERO LABS LIMITED |
Defendant | HETERO LABS LIMITED UNIT-V |
... |

- Search within this case
Analyze Party
Analyze Firm
Heron Therapeutics, Inc. v. Mylan Pharmaceuticals Inc.
Division | Wilmington |
Flags | PATENT |
Cause | 35:271 Patent Infringement |
Case Type | 835 Patent - Abbreviated New Drug Application (ANDA) |
Tags | 835 Patent, Abbreviated New Drug Application, Anda, 835 Patent, Abbreviated New Drug Application, Anda |
Deadline | IT IS HEREBY STIPULATED AND AGREED, by the parties, subject to the approval of the Court, that the following deadlines shall be modified as follows to accommodate the availability of the parties’ fact witnesses and to adjust the deadline for Case Dispositive Motions and Daubert Motions to the same deadline because the Scheduling Order requires them to be briefed together (D.I. 38 at ¶ 14): Event Currently Noticed Depositions Opening Expert Reports Responsive Expert Reports Reply Expert Reports Close of Expert Discovery Case Dispositive Motions Daubert Motions Trial Current Deadline N/A October 28, 2024 December 2, 2024 January 6, 2025 February 10, 2025 February 24, 2025 February 27, 2025 May 19, 2025 Stipulated Proposal October 22, 2024 November 15, 2024 December 20, 2024 January 17, 2025 February 21, 2025 February 28, 2025 February 28, 2025 May 19, 2025 (unchanged) No other deadlines in the Scheduling Order shall be affected by this stipulation., A 5 Day Bench Trial is set for 5/19/2025 - 5/23/2025 at 08:30 AM in To Be Determined before Judge William C. Bryson. |
Deadline | A 5 Day Bench Trial is set for 5/19/2025 - 5/23/2025 at 08:30 AM in To Be Determined before Judge William C. Bryson. |
Plaintiff | Heron Therapeutics, Inc. |
Defendant | Mylan Pharmaceuticals Inc. |
Counter Claimant | Mylan Pharmaceuticals Inc. |
... |

- Search within this case
Analyze Judge
Analyze Party
Analyze Firm
Sanofi-Aventis U.S. LLC v. Mylan GmbH
08/03/2021 | ... Appellees Biocon Ltd., Biocon Research Ltd., Biocon S.A., Biocon Sdn.Bhd and Mylan GmbH regarding conflicts with oral argument. None. Service: 08/03/2021 by email. [790319] [21-1262] [... |

- Search within this case
Analyze Judge
Analyze Party
Analyze Firm
Celgene Corporation v. Mylan Pharmaceuticals Inc.
05/11/2021 | 05/11/2021 38 Notice from Appellant Celgene Corporation regarding conflicts with oral argument. None. Service: 05/11/2021 by email. [774398] [21-1154] [Ellyde Th... |

- Search within this case
Analyze Judge
Analyze Party
Analyze Firm
Mylan Pharmaceuticals Inc. v. Bayer Intellectual Property GMBH et al
Division | Wilmington |
Flags | PATENT |
Cause | 35:1 Patent Infringement |
Case Type | 835 Patent - Abbreviated New Drug Application (ANDA) |
Tags | 835 Patent, Abbreviated New Drug Application, Anda, 835 Patent, Abbreviated New Drug Application, Anda |
Deadline | When the ’053 Patent expires, Mylan says that the FDA’s “longstanding practice” will convert Mylan’s ParagraphIVcertification into a ParagraphII certification® and cause a new pediatric exclusivity period to attach to the 053 Patent, foreclosing final approval until May 13, 2025., But Defendants cannotseriously dispute that, if Mylan were to obtain a judgmentof non-infringement on the ’053 Patent prior to November13, 2024, Mylan would have “prevailed”in its CAPC action, accelerating the timing of final approval to after February 28, 2025 (when pediatric exclusivity as to the °456 Patent expires), rather than after May 13, 2025 (when pediatric exclusivity as to the °053 Patent expires). |
Plaintiff | Mylan Pharmaceuticals Inc. |
Defendant | Bayer Intellectual Property GMBH |
Defendant | Bayer AG |
... |

- Search within this case
Analyze Judge
Analyze Party
Analyze Firm
Sanofi-Aventis Deutschland v. Mylan Pharmaceuticals, Inc.
08/09/2021 | 08/09/2021 90 Notice from Intervenor Andrew Hirshfeld regarding conflicts with oral argument. None. Service: 08/09/2021 by email. [791343] [20-2071] [Daniel Kazhd... |
08/03/2021 | 08/03/2021 88 Notice from Appellee Mylan Pharmaceuticals, Inc. regarding conflicts with oral argument. None. Service: 08/03/2021 by email. [790325] [20-2071] [Ric... |

- Search within this case
Analyze Judge
Analyze Party
Analyze Firm
Sanofi-Aventis Deutschland v. Mylan Pharmaceuticals Inc.
08/09/2021 | 08/09/2021 70 Notice from Intervenor Andrew Hirshfeld regarding conflicts with oral argument. None. Service: 08/09/2021 by email. [791340] [20-2066] [Brian Racilla... |
08/03/2021 | 08/03/2021 68 Notice from Appellee Mylan Pharmaceuticals Inc. regarding conflicts with oral argument. None. Service: 08/03/2021 by email. [790320] [20-2066] [Rich... |

- Search within this case
Analyze Judge
Analyze Party
Analyze Firm